Sector News

Shake-up at AstraZeneca as two immuno-oncology leaders leave

January 6, 2015
Life sciences
(Reuters) – AstraZeneca has appointed a new leader for its all-important immuno-oncology drug development operation after the departure of the previous head for personal reasons, the British-based drugmaker said on Monday.
 
Rachel Humphrey left the company at the end November and was replaced last month by Robert Iannone, a member of the global medicines development team, a spokeswoman said in response to inquiries. Her departure was not announced at the time.
 
Humphrey’s exit coincides with the loss of another leader in immuno-oncology, albeit from a different part of the firm. Peter Emtage, who was involved in early research at AstraZeneca’s unit MedImmune, was appointed to a senior position at biotech company Intrexon on Dec. 4.
 
AstraZeneca said the two departures were a coincidence and the company’s work in immuno-oncology was proceeding at full steam, with no problems with any programmes. “It’s business as usual,” the spokeswoman said.
 
The drugmaker, which saw off a $118 billion takeover attempt by Pfizer last year, is banking on new cancer medicines to help revive its fortunes.
 
It is also hoping for an imminent boost to its heart drug Brilinta from results of a clinical trial – known as PEGASUS – assessing the medicine’s use in patients who experienced a heart attack 1-3 years ago. That group could more than double the number of patients eligible for Brilinta. (Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”